LETTER FROM THE CHAIRMAN AND THE CEO
LUNDBECKFONDEN ANNUAL REPORT 2021
4
2021 was a strong year; the Lundbeck Foundation delivered the best financial result in its history, awarded a record level of grants, and took important steps forward in the realisation of its 2030 strategy.
LETTER FROM THE CHAIRMAN AND THE CEO
The financial performance allowed us to increase our grants to
perform well across all markets, delivering solid growth. This
public health research at the frontiers of medical science, to an
included the newest member of the Lundbeck product family,
all-time high level of DKK 803m, which was significantly
the preventative migraine treatment Vyepti®, which delivered
above our annual target of distributing a minimum of
according to plans in 2021 but has yet to fully recover the ground
DKK 500m.
lost due to COVID-19 delaying the US uptake in 2020. Nevertheless, in 2021 Vyepti® sales grew as planned in the USA
2021 was a year of new beginnings, as we began executing on
and other markets, and Lundbeck plans to launch the product in
our new strategy: Bringing Discoveries to Lives. This saw us
more countries in the future. We also started to see the impact
taking steps to align our new initiatives with existing activities,
from Lundbeck’s new and transformed approach to R&D,
2021 was an exceptional year for the Lundbeck Foundation,
while simultaneously building the platform for future value
which started to show progress in the early phases. In February
which awarded a record level of grants and delivered the best
creation. Achieving all of this demanded significant effort and
2022, Lundbeck announced the plan to introduce a new A and
financial result in its history.
commitment from our employees, both at the Foundation and
B share class structure to be adopted at an extraordinary general
its subsidiaries, and their collective dedication delivered
meeting in 2022. This initiative, instigated by the Foundation
further important progress towards our goals.
and developed in close dialogue with Lundbeck, has a clear
The year began amid widespread uncertainty, as the impact of the COVID-19 pandemic continued to be felt. However,
objective: to ensure that Lundbeck has every opportunity to
confidence began to return as societies reopened, which in turn
The past year has also been an important one for our
pursue and create value for patients and shareholders through
inspired renewed optimism and positive momentum for global
subsidiaries, Lundbeck, ALK and Falck.
organic growth, partnerships and acquisitions, while
economies and the financial markets. In 2021, the Foundation
maintaining the Foundation’s long-term commitment and
delivered the best financial result in its history, with a profit of
Despite a challenging market and pipeline, Lundbeck
DKK 6,928m – a considerable increase on the previous record
maintained its strategic trajectory and delivered financial results
profit of DKK 5,214m, which was delivered in 2019.
within its guidance for 2021. Its strategic brands continued to
majority ownership. ALK continued its progress with a strong 2021, during which,
